Zonisamide is an anti-seizure medication primarily used to treat focal (partial) seizures in adults with epilepsy. Sold under the brand name Zonegran, it’s FDA-approved as an add-on therapy for people aged 16 and older whose seizures aren’t fully controlled by other medications. Beyond epilepsy, zonisamide has gained attention for off-label uses in Parkinson’s disease and weight management.
How Zonisamide Works
Zonisamide belongs to a class called sulfonamide anticonvulsants, and it works through multiple pathways in the brain. Its primary effects involve blocking the repetitive firing of sodium channels and reducing certain calcium currents in neurons. Together, these actions help prevent the abnormal electrical surges that trigger seizures. The drug also weakly inhibits an enzyme called carbonic anhydrase, though this doesn’t appear to be its main seizure-fighting mechanism since much higher doses are needed compared to drugs that rely on that pathway.
This multi-target approach is one reason zonisamide can be effective when other single-mechanism medications fall short.
Epilepsy: The Primary Use
Zonisamide is approved specifically for focal-onset seizures, the most common seizure type in adults. These seizures start in one area of the brain and may or may not spread to cause a full-body convulsive episode. In most cases, zonisamide is added to an existing anti-seizure regimen rather than used alone, though some prescribing guidelines support it as a solo treatment for newly diagnosed patients.
The drug is not FDA-approved for children under 16. While some clinicians prescribe it off-label in pediatric cases, the American Academy of Neurology’s 2025 update on anti-seizure medications confirms that pediatric use remains outside official FDA approval.
What to Expect With Dosing
Zonisamide has a long half-life, meaning it stays in the body for an extended period. This allows for once-daily dosing in many cases but also means it can take up to two weeks to reach stable levels in the blood after any dose change. Because of this, doctors increase the dose gradually over several weeks.
When used as an add-on therapy, the typical starting dose is 50 mg per day, increasing in 100 mg increments over several weeks until reaching a maintenance dose of 300 to 500 mg daily. As a standalone treatment, patients usually begin at 100 mg per day and work up to a maintenance dose around 300 mg. Stopping zonisamide also requires a gradual taper, typically reducing by 100 mg per week, to avoid rebound seizures.
Off-Label Use in Parkinson’s Disease
Zonisamide has an approved indication for Parkinson’s disease in Japan, where it’s marketed under the brand name Trerief. In the United States, this use remains off-label, but the evidence behind it is notable.
In clinical trials involving 212 patients, a daily dose of 50 mg reduced “off” time (periods when Parkinson’s medications wear off and symptoms return) by nearly an hour per day compared to placebo. The same dose also significantly eased dyskinesia, the involuntary movements that are a common side effect of long-term Parkinson’s treatment. A lower 25 mg dose showed only a slight, statistically insignificant benefit. The proportion of patients who experienced both reduced off time and meaningful improvement in dyskinesia was about 12.5% on the higher dose, compared to just 2.7% on placebo.
Weight Loss Effects
Weight loss is a well-documented side effect of zonisamide, and some clinicians prescribe it off-label for weight management. The mechanism likely involves appetite suppression, though the exact pathway isn’t fully understood. This effect can be a welcome benefit for patients who need seizure control and struggle with weight, but it’s also something to watch for in patients who don’t want to lose weight. Zonisamide is not FDA-approved for weight loss, and its use for this purpose is considerably less studied than its epilepsy indication.
Side Effects and Risks
The most common side effects include drowsiness, dizziness, loss of appetite, and difficulty concentrating. Cognitive effects like mental slowing and word-finding difficulties are reported by some patients, particularly at higher doses.
Two less common but clinically important risks deserve attention:
- Kidney stones: About 4% of adults in clinical trials developed kidney stones while taking zonisamide. In pediatric patients monitored with ultrasound, the rate was even higher at 8%. Staying well-hydrated is an important preventive measure.
- Metabolic acidosis: Zonisamide can lower bicarbonate levels in the blood, making it more acidic than normal. Doctors typically check bicarbonate levels before starting the drug and periodically during treatment. Persistent acidosis may require dose reduction, discontinuation, or treatment to restore normal levels.
Sulfa Allergy Concerns
Because zonisamide is a sulfonamide compound, patients with sulfa allergies sometimes worry about cross-reactivity. The American Academy of Allergy, Asthma, and Immunology notes that cross-reactivity between antimicrobial sulfonamides (like sulfamethoxazole) and non-antimicrobial sulfonamides (like zonisamide) has not been conclusively established. There is no strong evidence that a reaction to one type predicts a reaction to the other. That said, for patients who have experienced severe reactions like Stevens-Johnson syndrome, some clinicians choose to avoid all sulfonamide medications as a precaution, even though evidence doesn’t clearly support that approach.